Cargando…
Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
PURPOSE: There are no reports on the use of neoadjuvant chemotherapy (NAC) in non-squamous cell cervical carcinoma. We examined the effectiveness and safety of paclitaxel/carboplatin (TC) and docetaxel/carboplatin (DC). METHODS: Stage Ib2 to IIb disease was present in 23 patients scheduled for radic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579421/ https://www.ncbi.nlm.nih.gov/pubmed/23263187 http://dx.doi.org/10.1007/s00280-012-2052-2 |
_version_ | 1782260127229804544 |
---|---|
author | Shoji, Tadahiro Takatori, Eriko Saito, Tatsunori Omi, Hideo Kagabu, Masahiro Miura, Fumiharu Takeuchi, Satoshi Sugiyama, Toru |
author_facet | Shoji, Tadahiro Takatori, Eriko Saito, Tatsunori Omi, Hideo Kagabu, Masahiro Miura, Fumiharu Takeuchi, Satoshi Sugiyama, Toru |
author_sort | Shoji, Tadahiro |
collection | PubMed |
description | PURPOSE: There are no reports on the use of neoadjuvant chemotherapy (NAC) in non-squamous cell cervical carcinoma. We examined the effectiveness and safety of paclitaxel/carboplatin (TC) and docetaxel/carboplatin (DC). METHODS: Stage Ib2 to IIb disease was present in 23 patients scheduled for radical hysterectomy. We administered 1–3 courses of either the TC or the DC regimen. Anti-tumor effects were found superior by Response Evaluation Criteria in Solid Tumors. Safety was assessed with National Cancer Institute Common Terminology Criteria for Adverse Events. RESULTS: Median age was 50 years (range 32–63 years), with stage Ib2 in 6 cases (26.1 %) and IIb in 17 cases (73.9 %). Complete response was achieved in 5 cases (21.7 %), partial response in 13 (56.5 %), stable disease in 5 (21.7 %); the response rate was 78.3 %, and surgery completion rate was 78.3 %. Leukopenia or neutropenia ≥grade 3 was seen in 12 (52.2 %) and 21 (91.3 %) cases, respectively, with grade 3 febrile neutropenia in 2 cases (8.7 %) and no anemia or thrombocytopenia ≥grade 3. Median progression-free survival was 26 months (95 % Cl, 13.5–38.5 months); median overall survival was 35 months (95 % Cl, 20.9–49.1 months). CONCLUSION: NAC for non-squamous cell cervical carcinoma showed potent anti-tumor effects and manageable adverse events. |
format | Online Article Text |
id | pubmed-3579421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-35794212013-02-26 Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix Shoji, Tadahiro Takatori, Eriko Saito, Tatsunori Omi, Hideo Kagabu, Masahiro Miura, Fumiharu Takeuchi, Satoshi Sugiyama, Toru Cancer Chemother Pharmacol Original Article PURPOSE: There are no reports on the use of neoadjuvant chemotherapy (NAC) in non-squamous cell cervical carcinoma. We examined the effectiveness and safety of paclitaxel/carboplatin (TC) and docetaxel/carboplatin (DC). METHODS: Stage Ib2 to IIb disease was present in 23 patients scheduled for radical hysterectomy. We administered 1–3 courses of either the TC or the DC regimen. Anti-tumor effects were found superior by Response Evaluation Criteria in Solid Tumors. Safety was assessed with National Cancer Institute Common Terminology Criteria for Adverse Events. RESULTS: Median age was 50 years (range 32–63 years), with stage Ib2 in 6 cases (26.1 %) and IIb in 17 cases (73.9 %). Complete response was achieved in 5 cases (21.7 %), partial response in 13 (56.5 %), stable disease in 5 (21.7 %); the response rate was 78.3 %, and surgery completion rate was 78.3 %. Leukopenia or neutropenia ≥grade 3 was seen in 12 (52.2 %) and 21 (91.3 %) cases, respectively, with grade 3 febrile neutropenia in 2 cases (8.7 %) and no anemia or thrombocytopenia ≥grade 3. Median progression-free survival was 26 months (95 % Cl, 13.5–38.5 months); median overall survival was 35 months (95 % Cl, 20.9–49.1 months). CONCLUSION: NAC for non-squamous cell cervical carcinoma showed potent anti-tumor effects and manageable adverse events. Springer-Verlag 2012-12-23 2013 /pmc/articles/PMC3579421/ /pubmed/23263187 http://dx.doi.org/10.1007/s00280-012-2052-2 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Article Shoji, Tadahiro Takatori, Eriko Saito, Tatsunori Omi, Hideo Kagabu, Masahiro Miura, Fumiharu Takeuchi, Satoshi Sugiyama, Toru Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix |
title | Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix |
title_full | Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix |
title_fullStr | Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix |
title_full_unstemmed | Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix |
title_short | Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix |
title_sort | neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage ib2 to iib non-squamous cell carcinoma of the uterine cervix |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579421/ https://www.ncbi.nlm.nih.gov/pubmed/23263187 http://dx.doi.org/10.1007/s00280-012-2052-2 |
work_keys_str_mv | AT shojitadahiro neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix AT takatorieriko neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix AT saitotatsunori neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix AT omihideo neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix AT kagabumasahiro neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix AT miurafumiharu neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix AT takeuchisatoshi neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix AT sugiyamatoru neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix |